<DOC>
	<DOC>NCT00840918</DOC>
	<brief_summary>This study is being done to determine if lidocaine, administered during surgery and for 24 hours after surgery can reduce inflammation, thereby reducing the risk of atrial fibrillation and 30 day mortality after surgery. Participants undergoing cardiac surgery will be randomized to receive either lidocaine or placebo.</brief_summary>
	<brief_title>Intravenous Lidocaine and Postoperative Outcomes After Cardiac Surgery</brief_title>
	<detailed_description>Subjects undergoing cardiac surgery are randomized into one of two groups. - Group 1: Intravenous Lidocaine Group - Group 2: Intravenous placebo Group Either Lidocaine or placebo is administered throughout surgery and 24 hours after surgery. Patients in both groups will undergo quality of life assessments and functional recovery assessments post-surgery.</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Age 1890 years old Scheduled for cardiac surgery requiring cardiopulmonary bypass Written informed consent Offpump surgical procedures Anticipated deep hypothermic circulatory arrest Any contraindications to the proposed interventions including lidocaine allergy History of preoperative atrial fibrillation Baseline Screening revealing preexisting dementia or delirium Preoperative liver failure defined as ChildPugh Score &gt; 6</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cardiac surgery</keyword>
	<keyword>Lidocaine</keyword>
	<keyword>Quality of life</keyword>
</DOC>